Evaluation of prazosin effects on depression

The effect of prazosin on improving sleep quality in patients with depressive disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210409050910N1

Enrollment

Registered

2021-05-24

Start date

2021-04-29

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep problems in patients with depressive disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Control group: Patients admitted to this group receive a placebo with exactly the same characteristics as the drug used in the study (prazosin). Placebo, like the drug under study, is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmation of depression disorder by Beck inventory Confirmation of sleep disorders by Pittsburg sleep quality index. Failed to respond to other ordinary medication of sleep disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sleep quality of patients with depressive disorder. Timepoint: Weeks 0, 4 and 8 after starting prazosin. Method of measurement: Pittsburgh Sleep Quality Index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Fahimi

Sabzevar University of Medical Sciences

hossein1fahimi@gmail.com+98 51 4465 1300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026